145 related articles for article (PubMed ID: 16260636)
1. The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus.
Zuccollo A; Shi C; Mastroianni R; Maitland-Toolan KA; Weisbrod RM; Zang M; Xu S; Jiang B; Oliver-Krasinski JM; Cayatte AJ; Corda S; Lavielle G; Verbeuren TJ; Cohen RA
Circulation; 2005 Nov; 112(19):3001-8. PubMed ID: 16260636
[TBL] [Abstract][Full Text] [Related]
2. The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice.
Xu S; Jiang B; Maitland KA; Bayat H; Gu J; Nadler JL; Corda S; Lavielle G; Verbeuren TJ; Zuccollo A; Cohen RA
Diabetes; 2006 Jan; 55(1):110-9. PubMed ID: 16380483
[TBL] [Abstract][Full Text] [Related]
3. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis.
Cayatte AJ; Du Y; Oliver-Krasinski J; Lavielle G; Verbeuren TJ; Cohen RA
Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1724-8. PubMed ID: 10894809
[TBL] [Abstract][Full Text] [Related]
4. [Terutroban and endothelial TP receptors in atherogenesis].
Verbeuren TJ
Med Sci (Paris); 2006 Apr; 22(4):437-43. PubMed ID: 16597416
[TBL] [Abstract][Full Text] [Related]
5. Altered TP receptor function in isolated, perfused kidneys of nondiabetic and diabetic ApoE-deficient mice.
Michel F; Simonet S; Vayssettes-Courchay C; Bertin F; Sansilvestri-Morel P; Bernhardt F; Paysant J; Silvestre JS; Levy BI; Félétou M; Verbeuren TJ
Am J Physiol Renal Physiol; 2008 Jan; 294(1):F120-9. PubMed ID: 17942572
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.
Egan KM; Wang M; Fries S; Lucitt MB; Zukas AM; Puré E; Lawson JA; FitzGerald GA
Circulation; 2005 Jan; 111(3):334-42. PubMed ID: 15655126
[TBL] [Abstract][Full Text] [Related]
7. Thromboxane A2/prostaglandin H2 receptor activation mediates angiotensin II-induced postischemic neovascularization.
Michel F; Silvestre JS; Waeckel L; Corda S; Verbeuren T; Vilaine JP; Clergue M; Duriez M; Levy BI
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):488-93. PubMed ID: 16385086
[TBL] [Abstract][Full Text] [Related]
8. Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban).
van der Hoorn JW; Jukema JW; Bekkers ME; Princen HM; Corda S; Emeis JJ; Steendijk P
Crit Care Med; 2008 Sep; 36(9):2576-82. PubMed ID: 18679128
[TBL] [Abstract][Full Text] [Related]
9. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice.
Kobayashi T; Tahara Y; Matsumoto M; Iguchi M; Sano H; Murayama T; Arai H; Oida H; Yurugi-Kobayashi T; Yamashita JK; Katagiri H; Majima M; Yokode M; Kita T; Narumiya S
J Clin Invest; 2004 Sep; 114(6):784-94. PubMed ID: 15372102
[TBL] [Abstract][Full Text] [Related]
10. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study.
Viles-Gonzalez JF; Fuster V; Corti R; Valdiviezo C; Hutter R; Corda S; Anand SX; Badimon JJ
Eur Heart J; 2005 Aug; 26(15):1557-61. PubMed ID: 15734766
[TBL] [Abstract][Full Text] [Related]
11. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
Vilahur G; Casaní L; Badimon L
Thromb Haemost; 2007 Sep; 98(3):662-9. PubMed ID: 17849057
[TBL] [Abstract][Full Text] [Related]
12. Renal effects of S18886 (Terutroban), a TP receptor antagonist, in an experimental model of type 2 diabetes.
Sebeková K; Eifert T; Klassen A; Heidland A; Amann K
Diabetes; 2007 Apr; 56(4):968-74. PubMed ID: 17267764
[TBL] [Abstract][Full Text] [Related]
13. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice.
Custodis F; Baumhäkel M; Schlimmer N; List F; Gensch C; Böhm M; Laufs U
Circulation; 2008 May; 117(18):2377-87. PubMed ID: 18443241
[TBL] [Abstract][Full Text] [Related]
14. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo.
Veillard NR; Steffens S; Pelli G; Lu B; Kwak BR; Gerard C; Charo IF; Mach F
Circulation; 2005 Aug; 112(6):870-8. PubMed ID: 16061736
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of uremia in apolipoprotein E-deficient mice.
Bro S
Dan Med Bull; 2009 Nov; 56(4):177-92. PubMed ID: 19939336
[TBL] [Abstract][Full Text] [Related]
16. BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase.
Cherdon C; Rolin S; Hanson J; Ooms A; de Leval L; Drion P; Michiels C; Pirotte B; Masereel B; Sakalihassan N; Defraigne JO; Dogné JM
Prostaglandins Other Lipid Mediat; 2011 Apr; 94(3-4):124-32. PubMed ID: 21397034
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis.
Ihara Y; Egashira K; Nakano K; Ohtani K; Kubo M; Koga J; Iwai M; Horiuchi M; Gang Z; Yamagishi S; Sunagawa K
J Mol Cell Cardiol; 2007 Oct; 43(4):455-64. PubMed ID: 17761193
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor-alpha does not mediate diabetes-induced vascular inflammation in mice.
Nilsson-Ohman J; Fredrikson GN; Nilsson-Berglund LM; Gustavsson C; Bengtsson E; Smith ML; Agardh CD; Agardh E; Jovinge S; Gomez MF; Nilsson J
Arterioscler Thromb Vasc Biol; 2009 Oct; 29(10):1465-70. PubMed ID: 19755528
[TBL] [Abstract][Full Text] [Related]
19. Endothelial nitric oxide deficiency reduces MMP-13-mediated cleavage of ICAM-1 in vascular endothelium: a role in atherosclerosis.
Tarín C; Gomez M; Calvo E; López JA; Zaragoza C
Arterioscler Thromb Vasc Biol; 2009 Jan; 29(1):27-32. PubMed ID: 18988893
[TBL] [Abstract][Full Text] [Related]
20. S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits.
Worth NF; Berry CL; Thomas AC; Campbell JH
Atherosclerosis; 2005 Nov; 183(1):65-73. PubMed ID: 15950232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
